MEN-10755 in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed hormone-refractory adenocarcinoma of the prostate
• Disease progression while on prior luteinizing hormone-releasing hormone (LHRH) analogues or after orchiectomy and antiandrogens, given concurrently or consecutively
• Disease progression is defined as PSA progression documented by increases in PSA recorded at 2 consecutive measurements over a prior reference value
• * Interval of at least 1 week between the reference value and the first of these two PSA increases
• Continued elevation of PSA for at least 6 weeks after discontinuation of antiandrogens
• Last PSA value at least 5 ng/mL (Hybritech equivalent)
• Must have serum testosterone less than 50 ng/mL and must continue on LHRH agonist therapy if no prior surgical castration
• No symptomatic brain or leptomeningeal metastatic disease
• PATIENT CHARACTERISTICS:
• Age:
• Over 18
• Performance status:
• ECOG 0-2
• Life expectancy:
• Not specified
• Hematopoietic:
• Neutrophil count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Hepatic:
• Bilirubin less than 1.5 times upper limit of normal (ULN)
• ALT/AST no greater than 2.5 times ULN (5 times ULN if liver metastases present)
• Renal:
• Creatinine no greater than 1.7 mg/dL
• No uncontrolled hypercalcemia
• Cardiovascular:
• No history of severe heart disease
• No myocardial infarction within the past 6 months
• No cardiac insufficiency
• Normal cardiac function by MUGA scan and 12-lead EKG
• Other:
• No other prior or concurrent malignancy except basal cell or squamous cell skin cancer
• No uncontrolled systemic nonmalignant disease or infection
• No psychological, familial, or geographical conditions that would preclude compliance
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• Not specified
• Chemotherapy:
• At least 4 weeks since prior chemotherapy
• Endocrine therapy:
• See Disease Characteristics
• No prior hormonal therapy except estramustine
• No concurrent estramustine
• Radiotherapy:
• At least 4 weeks since prior radiotherapy
• No concurrent radiotherapy (e.g., for painful bone metastases)
• Surgery:
• See Disease Characteristics
• Other:
• No other concurrent experimental drugs or investigational therapy